CClinicalTrials.gg
CompletedNCT03950089OPACITYUpdated May 15, 2019

Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC)

An observational study in Central Serous Chorioretinopathy, sponsored by Hospices Civils de Lyon. Completed. Per ClinicalTrials.gov, last updated 2019-05-15.

Sponsored by Hospices Civils de Lyon · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Sex
All
01

Study summary

Optical Coherence Tomography Angiography (OCT-A) is a noninvasive imaging technique that allows one to see blood vessels in the retina. The investigating team used this approach in patients with acute, recurrent and persistent subtypes of Central Serous Chorioretinopathy (CSC) to check for possible Choriocapillaris hypoperfusion. The presence or absence of these microvascular changes was explored in both eyes of the patients and compared to a control group of healthy volunteers. The possibility of a correlation between Choriocapillaris flow deficits, age and spontaneous resolution of serous retinal detachment was also evaluated. This study was conducted in an effort to improve one's understanding of this disease and other pachychoroid disorders.

02

Conditions studied

  • Central Serous Chorioretinopathy
03

In context

Central Serous Chorioretinopathy

86 studies on the registry are indexed under Central Serous Chorioretinopathy; 13 are open to participants now.

This study's enrollment of 120 is above the median of 83 across 21 observational studies indexed under Central Serous Chorioretinopathy.

Browse Central Serous Chorioretinopathy studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with acute, recurrent or persistent forms of central serous chorioretinopathy

Inclusion criteria

  • Patients with acute, recurrent or persistent forms of central serous chorioretinopathy

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic central serous chorioretinopathy were not eligible for inclusion
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Central Serous Chorioretinopathy

    Device: Optical Coherence Tomography Angiography (OCT-A)

  • Healthy patients

    Device: Optical Coherence Tomography Angiography (OCT-A)

Interventions

  • DeviceOptical Coherence Tomography Angiography (OCT-A)

    Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.

06

What researchers measure

Primary outcomes

  1. Total number average individual area of flow signal voids

    3x3 Optical Coherence Tomography Angiography (OCT-A) images on choriocapillaris slab were exported from the Angioplex software and then imported into the open-source Fiji software. Each image was binarized in black and white pixels. Thresholded areas greater than or equal to 1 white pixel were considered as flow signal voids

    Time frame: 2 months

  2. Total area of flow signal voids

    3x3 Optical Coherence Tomography Angiography (OCT-A) images on choriocapillaris slab were exported from the Angioplex software and then imported into the open-source Fiji software. Each image was binarized in black and white pixels. Thresholded areas greater than or equal to 1 white pixel were considered as flow signal voids

    Time frame: 2 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03950089
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
May 15, 2019
Start date
Jul 1, 2016
Primary completion
Sep 30, 2017
Completion
Sep 30, 2017
Last update
May 15, 2019

Study contacts

Thibaud Mathis, MD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion